Expert consensus on breast cancer screening in Chinese female with dense breast (2025 edition)_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 JING Jing

Committee for Integrative Prevention and Screening of Breast Cancer, China Anti-Cancer Association;

Corresponding?author：

JING Jing, Email: jingjing@wchscu.edu.cn

Keywords：

dense breast; Chinese female; breast cancer; screening expert consensus; early diagnosis; early treatment; prevention and control

DOI：

10.7507/1007-9424.202509027

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Dense breast is an independent risk factor for females with breast cancer, and also one of the important reasons for decreased sensitivity of mammography and increased risk of missed diagnosis. Females with dense breast in China account for a high proportion, making the breast cancer screening a key and difficult point in the prevention and control targeting breast cancer in such population. The formulation of specialized screening expert consensus for dense breast populations is conducive to achieving more accurate early detection, improving screening efficiency, and reasonably allocating medical resources. Committee for Integrative Prevention and Screening of Breast Cancer, China Anti-Cancer Association takes the lead and organizes multi-disciplinary experts to systematically review relevant evidence-based medical evidence domestically and internationally, integrate the actual situation, and clinical experience of China, and conform to setting norms of international guidelines to complete evidence integration and form recommendations, thereby formulating “Expert Consensus on Breast Cancer Screening in Chinese Female with Dense Breast (2025 edition)”. This expert consensus puts forward recommendations on the risk stratification, screening age, screening interval, screening methods, joint screening strategies, and other key issues of females with dense breast, aiming to promote the standardized screening practice of such population, improve the level of early diagnosis and treatment of breast cancer, and provide technical support and implementation basis for the prevention and control of Chinese females with breast cancer.

Citation： JING Jing. Expert consensus on breast cancer screening in Chinese female with dense breast (2025 edition). CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2025, 32(11): 1345-1360. doi: 10.7507/1007-9424.202509027 Copy

1.	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
2.	Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med, 2025, 31(4): 1154-1162.
3.	國家衛生健康委員會. 中國衛生健康統計年鑒, 2024. https://www.stats.gov.cn/sj/ndsj/2024/indexch.htm.
4.	鄭榮壽, 陳茹, 韓冰峰, 等. 2022年中國惡性腫瘤流行情況分析. 中華腫瘤雜志, 2024, 46(3): 221-231.
5.	鄔昊, 呂青. 全球及中國乳腺癌的流行病學趨勢及防控啟示: 2018–2022年《全球癌癥統計報告》解讀. 中國普外基礎與臨床雜志, 2024, 31(7): 796-802.
6.	Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol, 2024, 10(1): 71-78.
7.	Zhang L, Mosquera I, Lucas E, et al. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. Nat Med, 2023, 29(5): 1135-1145.
8.	Molassiotis A, Tyrovolas S, Giné-Vázquez I, et al. Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. ESMO Open, 2021, 6(3): 100111. doi: 10.1016/j.esmoop.2021.100111.
9.	US Preventive Services Task Force; Nicholson WK, Silverstein M, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA, 2024, 331(22): 1918-1930.
10.	Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med, 2003, 138(3): 168-175.
11.	Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
12.	鄧通, 汪洋, 黃笛, 等. 臨床實踐指南制訂方法—GRADE方法理論篇. 中國循證心血管醫學雜志, 2018, 10(12): 1441-1445.
13.	赫捷, 陳萬青, 李霓, 等. 中國女性乳腺癌篩查與早診早治指南(2021, 北京). 中華腫瘤雜志, 2021, 43(4): 357-382.
14.	中國抗癌協會乳腺癌專業委員會. 中國乳腺癌篩查與早期診斷指南. 中國癌癥雜志, 2022, 32(4): 363-372.
15.	中國研究型醫院學會乳腺專業委員會中國女性乳腺癌篩查指南制定專家組. 中國女性乳腺癌篩查指南(2022年版). 中國研究型醫院, 2022, 9(2): 6-13.
16.	中國抗癌協會乳腺癌專業委員會, 中華醫學會腫瘤學分會乳腺腫瘤學組. 中國抗癌協會與中華醫學會腫瘤學分會乳腺癌診治指南與規范(2025年版精要本). 上海: 復旦大學出版社, 2024.
17.	中國抗癌協會. 中國腫瘤整合診治指南(CACA), 2025. https://cacaguidelines.cacakp.com/pdflist/detail?id=420.
18.	中華預防醫學會. 中國女性乳腺癌篩查標準(T/CPMA 014-2020). 中華腫瘤雜志, 2021, 43(1): 8-15.
19.	陳可欣, 陳萬青, 黃育北, 等. 常見惡性腫瘤聯合篩查專家共識(2025版). 中國腫瘤, 2025, 34(8): 583-610.
20.	Expert Panel on Breast Imaging; Niell BL, Jochelson MS, et al. ACR Appropriateness Criteria? female breast cancer screening: 2023 update. J Am Coll Radiol, 2024, 21(6S): S126-S143. doi: 10.1016/j.jacr.2024.02.019.
21.	Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3. 2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2024, 22(5): 331-357.
22.	Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol, 2024, 35(2): 159-182.
23.	Dai H, Yan Y, Wang P, et al. Distribution of mammographic density and its influential factors among Chinese women. Int J Epidemiol, 2014, 43(4): 1240-1251.
24.	Spak DA, Plaxco JS, Santiago L, et al. BI-RADS? fifth edition: a summary of changes. Diagn Interv Imaging, 2017, 98(3): 179-190.
25.	Acciavatti RJ, Lee SH, Reig B, et al. Beyond breast density: risk measures for breast cancer in multiple imaging modalities. Radiology, 2023, 306(3): e222575. doi: 10.1148/radiol.222575.
26.	Kerlikowske K, Bissell MCS, Sprague BL, et al. Impact of BMI on prevalence of dense breasts by race and ethnicity. Cancer Epidemiol Biomarkers Prev, 2023, 32(11): 1524-1530.
27.	于代友, 劉秀梅, 陳雯, 等. 女性乳腺密度與年齡及乳腺癌的相關性研究. 實用腫瘤學雜志, 2016, 30(4): 295-299.
28.	Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med, 2016, 164(4): 268-278.
29.	Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27 825 patient evaluations. Radiology, 2002, 225(1): 165-175.
30.	Freer PE. Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics, 2015, 35(2): 302-315.
31.	Wanders JO, Holland K, Veldhuis WB, et al. Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat, 2017, 162(1): 95-103.
32.	Glechner A, Wagner G, Mitus JW, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev, 2023, 3(3): CD009632. doi: 10.1002/14651858.CD009632.pub3.
33.	Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol, 2016, 34(16): 1882-1888.
34.	Gilbert FJ, Payne NR, Allajbeu I, et al. Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial. Lancet, 2025, 405(10493): 1935-1944.
35.	Bodewes FTH, van Asselt AA, Dorrius MD, et al. Mammographic breast density and the risk of breast cancer: a systematic review and meta-analysis. Breast, 2022, 66: 62-68.
36.	Brem RF, Lenihan MJ, Lieberman J, et al. Screening breast ultrasound: past, present, and future. AJR Am J Roentgenol, 2015, 204(2): 234-240.
37.	Advani SM, Zhu W, Demb J, et al. Association of breast density with breast cancer risk among women aged 65 years or older by age group and body mass index. JAMA Netw Open, 2021, 4(8): e2122810. doi: 10.1001/jamanetworkopen.2021.22810.
38.	Farkas AH, Nattinger AB. Breast cancer screening and prevention. Ann Intern Med, 2023, 176(11): ITC161-ITC176. doi: 10.7326/AITC202311210.
39.	Park B, Chang Y, Ryu S, et al. Trajectories of breast density change over time and subsequent breast cancer risk: longitudinal study. BMJ, 2024, 387: e079575. doi: 10.1136/bmj-2024-079575.
40.	吳克瑾. 優化我國乳腺癌篩查策略與實施效果的思考. 中華外科雜志, 2018, 56(2): 101-105.
41.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
42.	Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer, 2023, 184: 39-47.
43.	Li A, Xie R, Zhi Q, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol, 2018, 151(1): 145-152.
44.	Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 2003, 72(5): 1117-1130.
45.	Durham DD, Abraham LA, Roberts MC, et al. Breast cancer incidence among women with a family history of breast cancer by relative’s age at diagnosis. Cancer, 2022, 128(24): 4232-4240.
46.	Hou C, Zhong X, He P, et al. Predicting breast cancer in Chinese women using machine learning techniques: algorithm development. JMIR Med Inform, 2020, 8(6): e17364. doi: 10.2196/17364.
47.	上海市衛生健康委員會人口監測與家庭發展處. 2024年上海市人口監測統計資料主要數據匯編. https://wsjkw.sh.gov.cn/tjsj2/20250226/56493f15c5a14146acfa66af3c8b2f84.html.
48.	World Obesity Federation. World Obesity Atlas 2025. London: World ObesityFederation, 2025. https://data.worldobesity.org/publications/?cat=23.
49.	張現苓, 盛亦男. 1990~2020年中國的婚育推遲: 變化趨勢與典型特征. 人口研究, 2023, 47(5): 88-101.
50.	Zheng D, Song L, Liu X, et al. Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China. Gland Surg, 2022, 11(5): 805-817.Zheng D, Song L, Liu X, et al. Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China. Gland Surg, 2022, 11(5): 805-817.
51.	Mascara M, Constantinou C. Global perceptions of women on breast cancer and barriers to screening. Curr Oncol Rep, 2021, 23(7): 74. doi: 10.1007/s11912-021-01069-z.
52.	Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet, 2012, 380(9855): 1778-1786.
53.	Nattinger AB, Mitchell JL. Breast cancer screening and prevention. Ann Intern Med, 2016, 164(11): ITC81-ITC96. doi: 10.7326/aitc201606070.
54.	中華人民共和國國家衛生健康委員會. 乳腺癌篩查工作方案. 2025. https://www.nhc.gov.cn/fys/c100078/202201/e4209b0a6e604f6aba3e793d8eddebf3/files/1733998298635_97783.pdf.
55.	國家衛生健康委員會. 《全國護理事業發展規劃(2021–2025年)》. 2022. https://www.nhc.gov.cn/yzygj/c100068/202205/5c2dc667011449428655582e19a6c9bd.shtml.
56.	Gupta R, Gupta S, Mehrotra R, et al. Risk factors of breast cancer and breast self-examination in early detection: systematic review of awareness among Indian women in community and health care professionals. J Public Health (Oxf), 2020, 42(1): 118-131.
57.	Venet L. Self-examination and clinical examination of the breast. Cancer, 1980, 46(4 Suppl): 930-932.
58.	Baines CJ. Breast self-examination. Cancer, 1992, 69(7 Suppl): 1942-1946.
59.	Alshafie M, Soqia J, Alhomsi D, et al. Knowledge and practice of breast self-examination among breast cancer patients in Damascus, Syria. BMC Womens Health, 2024, 24(1): 73. doi: 10.1186/s12905-024-02912-8.
60.	Husein S, Hanafi I, Balouli M, et al. Breast cancer screening during the Syrian crisis: a cross-sectional study. J Prev Med Hyg, 2021, 62(2): E520-E528. doi: 10.15167/2421-4248/jpmh2021.62.2.2056.
61.	Khan M, Chollet A. Breast cancer screening: common questions and answers. Am Fam Physician, 2021, 103(1): 33-41.
62.	No authors listed. Report of the Working Group to Review the National Cancer Institute-American Cancer Society breast cancer detection demonstration projects. J Natl Cancer Inst, 1979, 62(3): 639-709.
63.	Miller AB, Baines CJ, Turnbull C. The role of the nurse-examiner in the National Breast Screening Study. Can J Public Health, 1991, 82(3): 162-167.
64.	Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med, 2015, 372(24): 2353-2358.
65.	Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA, 2015, 314(15): 1615-1634.
66.	Amir T, Hogan MP, Jacobs S, et al. Comparison of false-positive versus true-positive findings on contrast-enhanced digital mammography. AJR Am J Roentgenol, 2022, 218(5): 797-808.
67.	Patel BK, Carnahan MB, Northfelt D, et al. Prospective study of supplemental screening with contrast-enhanced mammography in women with elevated risk of breast cancer: results of the prevalence round. J Clin Oncol, 2024, 42(32): 3826-3836.
68.	Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
69.	Geisel J, Raghu M, Hooley R. The role of ultrasound in breast cancer screening: the case for and against ultrasound. Semin Ultrasound CT MR, 2018, 39(1): 25-34.
70.	Rajaram N, Mariapun S, Eriksson M, et al. Differences in mammographic density between Asian and Caucasian populations: a comparative analysis. Breast Cancer Res Treat, 2017, 161(2): 353-362.
71.	Dong H, Huang Y, Song F, et al. Improved performance of adjunctive ultrasonography after mammography screening for breast cancer among Chinese females. Clin Breast Cancer, 2018, 18(3): e353-e361. doi: 10.1016/j.clbc.2017.07.014.
72.	Yang Y, Liu J, Gu R, et al. Influence of factors on mammographic density in premenopausal Chinese women. Eur J Cancer Prev, 2016, 25(4): 306-311.
73.	Hussein H, Abbas E, Keshavarzi S, et al. Supplemental breast cancer screening in women with dense breasts and negative mammography: a systematic review and meta-analysis. Radiology, 2023, 306(3): e221785. doi: 10.1148/radiol.221785.
74.	Lee SH, Ryu HS, Jang MJ, et al. Glandular tissue component and breast cancer risk in mammographically dense breasts at screening breast US. Radiology, 2021, 301(1): 57-65.
75.	Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet, 2016, 387(10016): 341-348.
76.	Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA, 2012, 307(13): 1394-1404.
77.	Wang Y, Chen H, Li N, et al. Ultrasound for breast cancer screening in high-risk women: results from a population-based cancer screening program in China. Front Oncol, 2019, 9: 286. doi: 10.3389/fonc.2019.00286.
78.	Rebolj M, Assi V, Brentnall A, et al. Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. Br J Cancer, 2018, 118(12): 1559-1570.
79.	Mei J, Hu Y, Wang H, et al. Development and validation of a clinical-bimodal nomogram to predict the malignancy of pathologic nipple discharge. Quant Imaging Med Surg, 2025, 15(10): 10081-10093.
80.	Mei J, Hu Y, Jiang X, et al. Ultrasound-guided vacuum-assisted biopsy versus surgical resection in patients with breast desmoid tumor. J Surg Res, 2021, 261: 400-406.
81.	Kwon MR, Choi JS, Lee MY, et al. Screening outcomes of supplemental automated breast US in Asian women with dense and nondense breasts. Radiology, 2023, 307(4): e222435. doi: 10.1148/radiol.222435.
82.	Aribal E, Seker ME, Guldogan N, et al. Value of automated breast ultrasound in screening: standalone and as a supplemental to digital breast tomosynthesis. Int J Cancer, 2024, 155(8): 1466-1475.
83.	Paul S, McPeek C, Lieberenz J, et al. Supplemental automated breast US screening in patients with dense breasts: 5-year experience from an academic medical center. J Breast Imaging, 2025, 7(1): 35-44.
84.	Hu Y, Mei J, Jiang X, et al. Does the radiologist need to rescan the breast lesion to validate the final BI-RADS US assessment made on the static images in the diagnostic setting?. Cancer Manag Res, 2019, 11: 4607-4615.
85.	楊雅平, 梁靜, 胡越, 等. 中國南方女性乳腺癌篩查“逸仙模式”初步結果分析. 中國科學(生命科學), 2020, 50(10): 1114-1120.
86.	Yang Y, Zhong Y, Li J, et al. Deep learning combining mammography and ultrasound images to predict the malignancy of BI-RADS US 4A lesions in women with dense breasts: a diagnostic study. Int J Surg, 2024, 110(5): 2604-2613.
87.	Yang Y, Hu Y, Shen S, et al. A new nomogram for predicting the malignant diagnosis of Breast Imaging Reporting and Data System (BI-RADS) ultrasonography category 4A lesions in women with dense breast tissue in the diagnostic setting. Quant Imaging Med Surg, 2021, 11(7): 3005-3017.
88.	Niell BL, Freer PE, Weinfurtner RJ, et al. Screening for breast cancer. Radiol Clin North Am, 2017, 55(6): 1145-1162.
89.	Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA, 2020, 323(8): 746-756.
90.	Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol, 2010, 28(9): 1450-1457.
91.	Lehman CD. Role of MRI in screening women at high risk for breast cancer. J Magn Reson Imaging, 2006, 24(5): 964-970.
92.	Veenhuizen SGA, de Lange SV, Bakker MF, et al. Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology, 2021, 299(2): 278-286.
93.	Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med, 2019, 381(22): 2091-2102.
94.	Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol, 2009, 27(33): 5640-5649.
95.	Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst, 2010, 102(10): 680-691.
96.	Stout NK, Miglioretti DL, Su YR, et al. Breast cancer screening using mammography, digital breast tomosynthesis, and magnetic resonance imaging by breast density. JAMA Intern Med, 2024, 184(10): 1222-1231.
97.	Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol, 2015, 25(12): 3669-3678.
98.	Mariscotti G, Houssami N, Durando M, et al. Accuracy of mammography, digital breast tomosynthesis, ultrasound and MR imaging in preoperative assessment of breast cancer. Anticancer Res, 2014, 34(3): 1219-1225.
99.	Alabousi M, Wadera A, Kashif Al-Ghita M, et al. Performance of digital breast tomosynthesis, synthetic mammography, and digital mammography in breast cancer screening: a systematic review and meta-analysis. J Natl Cancer Inst, 2021, 113(6): 680-690.
100.	Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA, 2014, 311(24): 2499-2507.
101.	Kulkarni S, Freitas V, Muradali D. Digital breast tomosynthesis: potential benefits in routine clinical practice. Can Assoc Radiol J, 2022, 73(1): 107-120.
102.	張振華, 李曼, 劉文霞. 廣角DBT與MRI在致密型乳腺惡性腫瘤的影像學特征及診斷. 醫學影像學雜志 2023, 33(9): 1603-1607.
103.	Expert Panel on Breast Imaging; Klein KA, Kocher M, et al. ACR Appropriateness Criteria? palpable breast masses: 2022 update. J Am Coll Radiol, 2023, 20(5S): S146-S163. doi: 10.1016/j.jacr.2023.02.013.
104.	Aristokli N, Polycarpou I, Themistocleous SC, et al. Comparison of the diagnostic performance of Magnetic Resonance Imaging (MRI), ultrasound and mammography for detection of breast cancer based on tumor type, breast density and patient’s history: A review. Radiography (Lond), 2022, 28(3): 848-856.
105.	阮程曉, 鄭穎娟. 彩色多普勒超聲聯合全數字化乳腺X線攝影診斷乳腺癌的臨床價值分析. 腫瘤基礎與臨床, 2025, 38(2): 220-223.
106.	國家癌癥中心/國家腫瘤臨床醫學研究中心/中國醫學科學院北京協和醫學院腫瘤醫院, 《健康體檢與管理》雜志編委會, 中華醫學會健康管理學分會, 等. 乳腺癌機會性篩查規范路徑專家共識. 健康體檢與管理, 2024, 5(1): 1-13.
107.	Brown AL, Vijapura C, Patel M, et al. Breast cancer in dense breasts: detection challenges and supplemental screening opportunities. Radiographics, 2023, 43(10): e230024. doi: 10.1148/rg.230024.
108.	Lynge E, Vejborg I, Lillholm M, et al. Breast density and risk of breast cancer. Int J Cancer, 2023, 152(6): 1150-1158.
109.	Hu Y, Yang Y, Gu R, et al. Does patient age affect the PPV3 of ACR BI-RADS ultrasound categories 4 and 5 in the diagnostic setting?. Eur Radiol, 2018, 28(6): 2492-2498.
110.	Checka CM, Chun JE, Schnabel FR, et al. The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol, 2012, 198(3): W292-W295. doi: 10.2214/AJR.10.6049.
111.	Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol, 2010, 28(12): 2038-2045.
112.	Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol, 2021, 22(7): e327-e340. doi: 10.1016/s1470-2045(20)30741-5.

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
2. Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med, 2025, 31(4): 1154-1162.
3. 國家衛生健康委員會. 中國衛生健康統計年鑒, 2024. https://www.stats.gov.cn/sj/ndsj/2024/indexch.htm.
4. 鄭榮壽, 陳茹, 韓冰峰, 等. 2022年中國惡性腫瘤流行情況分析. 中華腫瘤雜志, 2024, 46(3): 221-231.
5. 鄔昊, 呂青. 全球及中國乳腺癌的流行病學趨勢及防控啟示: 2018–2022年《全球癌癥統計報告》解讀. 中國普外基礎與臨床雜志, 2024, 31(7): 796-802.
6. Benitez Fuentes JD, Morgan E, de Luna Aguilar A, et al. Global stage distribution of breast cancer at diagnosis: a systematic review and meta-analysis. JAMA Oncol, 2024, 10(1): 71-78.
7. Zhang L, Mosquera I, Lucas E, et al. CanScreen5, a global repository for breast, cervical and colorectal cancer screening programs. Nat Med, 2023, 29(5): 1135-1145.
8. Molassiotis A, Tyrovolas S, Giné-Vázquez I, et al. Organized breast cancer screening not only reduces mortality from breast cancer but also significantly decreases disability-adjusted life years: analysis of the Global Burden of Disease Study and screening programme availability in 130 countries. ESMO Open, 2021, 6(3): 100111. doi: 10.1016/j.esmoop.2021.100111.
9. US Preventive Services Task Force; Nicholson WK, Silverstein M, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA, 2024, 331(22): 1918-1930.
10. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med, 2003, 138(3): 168-175.
11. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, 336(7650): 924-926.
12. 鄧通, 汪洋, 黃笛, 等. 臨床實踐指南制訂方法—GRADE方法理論篇. 中國循證心血管醫學雜志, 2018, 10(12): 1441-1445.
13. 赫捷, 陳萬青, 李霓, 等. 中國女性乳腺癌篩查與早診早治指南(2021, 北京). 中華腫瘤雜志, 2021, 43(4): 357-382.
14. 中國抗癌協會乳腺癌專業委員會. 中國乳腺癌篩查與早期診斷指南. 中國癌癥雜志, 2022, 32(4): 363-372.
15. 中國研究型醫院學會乳腺專業委員會中國女性乳腺癌篩查指南制定專家組. 中國女性乳腺癌篩查指南(2022年版). 中國研究型醫院, 2022, 9(2): 6-13.
16. 中國抗癌協會乳腺癌專業委員會, 中華醫學會腫瘤學分會乳腺腫瘤學組. 中國抗癌協會與中華醫學會腫瘤學分會乳腺癌診治指南與規范(2025年版精要本). 上海: 復旦大學出版社, 2024.
17. 中國抗癌協會. 中國腫瘤整合診治指南(CACA), 2025. https://cacaguidelines.cacakp.com/pdflist/detail?id=420.
18. 中華預防醫學會. 中國女性乳腺癌篩查標準(T/CPMA 014-2020). 中華腫瘤雜志, 2021, 43(1): 8-15.
19. 陳可欣, 陳萬青, 黃育北, 等. 常見惡性腫瘤聯合篩查專家共識(2025版). 中國腫瘤, 2025, 34(8): 583-610.
20. Expert Panel on Breast Imaging; Niell BL, Jochelson MS, et al. ACR Appropriateness Criteria? female breast cancer screening: 2023 update. J Am Coll Radiol, 2024, 21(6S): S126-S143. doi: 10.1016/j.jacr.2024.02.019.
21. Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3. 2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2024, 22(5): 331-357.
22. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol, 2024, 35(2): 159-182.
23. Dai H, Yan Y, Wang P, et al. Distribution of mammographic density and its influential factors among Chinese women. Int J Epidemiol, 2014, 43(4): 1240-1251.
24. Spak DA, Plaxco JS, Santiago L, et al. BI-RADS? fifth edition: a summary of changes. Diagn Interv Imaging, 2017, 98(3): 179-190.
25. Acciavatti RJ, Lee SH, Reig B, et al. Beyond breast density: risk measures for breast cancer in multiple imaging modalities. Radiology, 2023, 306(3): e222575. doi: 10.1148/radiol.222575.
26. Kerlikowske K, Bissell MCS, Sprague BL, et al. Impact of BMI on prevalence of dense breasts by race and ethnicity. Cancer Epidemiol Biomarkers Prev, 2023, 32(11): 1524-1530.
27. 于代友, 劉秀梅, 陳雯, 等. 女性乳腺密度與年齡及乳腺癌的相關性研究. 實用腫瘤學雜志, 2016, 30(4): 295-299.
28. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med, 2016, 164(4): 268-278.
29. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27 825 patient evaluations. Radiology, 2002, 225(1): 165-175.
30. Freer PE. Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics, 2015, 35(2): 302-315.
31. Wanders JO, Holland K, Veldhuis WB, et al. Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat, 2017, 162(1): 95-103.
32. Glechner A, Wagner G, Mitus JW, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev, 2023, 3(3): CD009632. doi: 10.1002/14651858.CD009632.pub3.
33. Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol, 2016, 34(16): 1882-1888.
34. Gilbert FJ, Payne NR, Allajbeu I, et al. Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial. Lancet, 2025, 405(10493): 1935-1944.
35. Bodewes FTH, van Asselt AA, Dorrius MD, et al. Mammographic breast density and the risk of breast cancer: a systematic review and meta-analysis. Breast, 2022, 66: 62-68.
36. Brem RF, Lenihan MJ, Lieberman J, et al. Screening breast ultrasound: past, present, and future. AJR Am J Roentgenol, 2015, 204(2): 234-240.
37. Advani SM, Zhu W, Demb J, et al. Association of breast density with breast cancer risk among women aged 65 years or older by age group and body mass index. JAMA Netw Open, 2021, 4(8): e2122810. doi: 10.1001/jamanetworkopen.2021.22810.
38. Farkas AH, Nattinger AB. Breast cancer screening and prevention. Ann Intern Med, 2023, 176(11): ITC161-ITC176. doi: 10.7326/AITC202311210.
39. Park B, Chang Y, Ryu S, et al. Trajectories of breast density change over time and subsequent breast cancer risk: longitudinal study. BMJ, 2024, 387: e079575. doi: 10.1136/bmj-2024-079575.
40. 吳克瑾. 優化我國乳腺癌篩查策略與實施效果的思考. 中華外科雜志, 2018, 56(2): 101-105.
41. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
42. Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer, 2023, 184: 39-47.
43. Li A, Xie R, Zhi Q, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol, 2018, 151(1): 145-152.
44. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet, 2003, 72(5): 1117-1130.
45. Durham DD, Abraham LA, Roberts MC, et al. Breast cancer incidence among women with a family history of breast cancer by relative’s age at diagnosis. Cancer, 2022, 128(24): 4232-4240.
46. Hou C, Zhong X, He P, et al. Predicting breast cancer in Chinese women using machine learning techniques: algorithm development. JMIR Med Inform, 2020, 8(6): e17364. doi: 10.2196/17364.
47. 上海市衛生健康委員會人口監測與家庭發展處. 2024年上海市人口監測統計資料主要數據匯編. https://wsjkw.sh.gov.cn/tjsj2/20250226/56493f15c5a14146acfa66af3c8b2f84.html.
48. World Obesity Federation. World Obesity Atlas 2025. London: World ObesityFederation, 2025. https://data.worldobesity.org/publications/?cat=23.
49. 張現苓, 盛亦男. 1990~2020年中國的婚育推遲: 變化趨勢與典型特征. 人口研究, 2023, 47(5): 88-101.
50. Zheng D, Song L, Liu X, et al. Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China. Gland Surg, 2022, 11(5): 805-817.Zheng D, Song L, Liu X, et al. Impact of financial support on the prognosis of HER2-positive breast cancer from 2002 to 2020: a prospective cohort from western China. Gland Surg, 2022, 11(5): 805-817.
51. Mascara M, Constantinou C. Global perceptions of women on breast cancer and barriers to screening. Curr Oncol Rep, 2021, 23(7): 74. doi: 10.1007/s11912-021-01069-z.
52. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet, 2012, 380(9855): 1778-1786.
53. Nattinger AB, Mitchell JL. Breast cancer screening and prevention. Ann Intern Med, 2016, 164(11): ITC81-ITC96. doi: 10.7326/aitc201606070.
54. 中華人民共和國國家衛生健康委員會. 乳腺癌篩查工作方案. 2025. https://www.nhc.gov.cn/fys/c100078/202201/e4209b0a6e604f6aba3e793d8eddebf3/files/1733998298635_97783.pdf.
55. 國家衛生健康委員會. 《全國護理事業發展規劃(2021–2025年)》. 2022. https://www.nhc.gov.cn/yzygj/c100068/202205/5c2dc667011449428655582e19a6c9bd.shtml.
56. Gupta R, Gupta S, Mehrotra R, et al. Risk factors of breast cancer and breast self-examination in early detection: systematic review of awareness among Indian women in community and health care professionals. J Public Health (Oxf), 2020, 42(1): 118-131.
57. Venet L. Self-examination and clinical examination of the breast. Cancer, 1980, 46(4 Suppl): 930-932.
58. Baines CJ. Breast self-examination. Cancer, 1992, 69(7 Suppl): 1942-1946.
59. Alshafie M, Soqia J, Alhomsi D, et al. Knowledge and practice of breast self-examination among breast cancer patients in Damascus, Syria. BMC Womens Health, 2024, 24(1): 73. doi: 10.1186/s12905-024-02912-8.
60. Husein S, Hanafi I, Balouli M, et al. Breast cancer screening during the Syrian crisis: a cross-sectional study. J Prev Med Hyg, 2021, 62(2): E520-E528. doi: 10.15167/2421-4248/jpmh2021.62.2.2056.
61. Khan M, Chollet A. Breast cancer screening: common questions and answers. Am Fam Physician, 2021, 103(1): 33-41.
62. No authors listed. Report of the Working Group to Review the National Cancer Institute-American Cancer Society breast cancer detection demonstration projects. J Natl Cancer Inst, 1979, 62(3): 639-709.
63. Miller AB, Baines CJ, Turnbull C. The role of the nurse-examiner in the National Breast Screening Study. Can J Public Health, 1991, 82(3): 162-167.
64. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer screening—viewpoint of the IARC Working Group. N Engl J Med, 2015, 372(24): 2353-2358.
65. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA, 2015, 314(15): 1615-1634.
66. Amir T, Hogan MP, Jacobs S, et al. Comparison of false-positive versus true-positive findings on contrast-enhanced digital mammography. AJR Am J Roentgenol, 2022, 218(5): 797-808.
67. Patel BK, Carnahan MB, Northfelt D, et al. Prospective study of supplemental screening with contrast-enhanced mammography in women with elevated risk of breast cancer: results of the prevalence round. J Clin Oncol, 2024, 42(32): 3826-3836.
68. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
69. Geisel J, Raghu M, Hooley R. The role of ultrasound in breast cancer screening: the case for and against ultrasound. Semin Ultrasound CT MR, 2018, 39(1): 25-34.
70. Rajaram N, Mariapun S, Eriksson M, et al. Differences in mammographic density between Asian and Caucasian populations: a comparative analysis. Breast Cancer Res Treat, 2017, 161(2): 353-362.
71. Dong H, Huang Y, Song F, et al. Improved performance of adjunctive ultrasonography after mammography screening for breast cancer among Chinese females. Clin Breast Cancer, 2018, 18(3): e353-e361. doi: 10.1016/j.clbc.2017.07.014.
72. Yang Y, Liu J, Gu R, et al. Influence of factors on mammographic density in premenopausal Chinese women. Eur J Cancer Prev, 2016, 25(4): 306-311.
73. Hussein H, Abbas E, Keshavarzi S, et al. Supplemental breast cancer screening in women with dense breasts and negative mammography: a systematic review and meta-analysis. Radiology, 2023, 306(3): e221785. doi: 10.1148/radiol.221785.
74. Lee SH, Ryu HS, Jang MJ, et al. Glandular tissue component and breast cancer risk in mammographically dense breasts at screening breast US. Radiology, 2021, 301(1): 57-65.
75. Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet, 2016, 387(10016): 341-348.
76. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA, 2012, 307(13): 1394-1404.
77. Wang Y, Chen H, Li N, et al. Ultrasound for breast cancer screening in high-risk women: results from a population-based cancer screening program in China. Front Oncol, 2019, 9: 286. doi: 10.3389/fonc.2019.00286.
78. Rebolj M, Assi V, Brentnall A, et al. Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. Br J Cancer, 2018, 118(12): 1559-1570.
79. Mei J, Hu Y, Wang H, et al. Development and validation of a clinical-bimodal nomogram to predict the malignancy of pathologic nipple discharge. Quant Imaging Med Surg, 2025, 15(10): 10081-10093.
80. Mei J, Hu Y, Jiang X, et al. Ultrasound-guided vacuum-assisted biopsy versus surgical resection in patients with breast desmoid tumor. J Surg Res, 2021, 261: 400-406.
81. Kwon MR, Choi JS, Lee MY, et al. Screening outcomes of supplemental automated breast US in Asian women with dense and nondense breasts. Radiology, 2023, 307(4): e222435. doi: 10.1148/radiol.222435.
82. Aribal E, Seker ME, Guldogan N, et al. Value of automated breast ultrasound in screening: standalone and as a supplemental to digital breast tomosynthesis. Int J Cancer, 2024, 155(8): 1466-1475.
83. Paul S, McPeek C, Lieberenz J, et al. Supplemental automated breast US screening in patients with dense breasts: 5-year experience from an academic medical center. J Breast Imaging, 2025, 7(1): 35-44.
84. Hu Y, Mei J, Jiang X, et al. Does the radiologist need to rescan the breast lesion to validate the final BI-RADS US assessment made on the static images in the diagnostic setting?. Cancer Manag Res, 2019, 11: 4607-4615.
85. 楊雅平, 梁靜, 胡越, 等. 中國南方女性乳腺癌篩查“逸仙模式”初步結果分析. 中國科學(生命科學), 2020, 50(10): 1114-1120.
86. Yang Y, Zhong Y, Li J, et al. Deep learning combining mammography and ultrasound images to predict the malignancy of BI-RADS US 4A lesions in women with dense breasts: a diagnostic study. Int J Surg, 2024, 110(5): 2604-2613.
87. Yang Y, Hu Y, Shen S, et al. A new nomogram for predicting the malignant diagnosis of Breast Imaging Reporting and Data System (BI-RADS) ultrasonography category 4A lesions in women with dense breast tissue in the diagnostic setting. Quant Imaging Med Surg, 2021, 11(7): 3005-3017.
88. Niell BL, Freer PE, Weinfurtner RJ, et al. Screening for breast cancer. Radiol Clin North Am, 2017, 55(6): 1145-1162.
89. Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA, 2020, 323(8): 746-756.
90. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol, 2010, 28(9): 1450-1457.
91. Lehman CD. Role of MRI in screening women at high risk for breast cancer. J Magn Reson Imaging, 2006, 24(5): 964-970.
92. Veenhuizen SGA, de Lange SV, Bakker MF, et al. Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology, 2021, 299(2): 278-286.
93. Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med, 2019, 381(22): 2091-2102.
94. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol, 2009, 27(33): 5640-5649.
95. Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst, 2010, 102(10): 680-691.
96. Stout NK, Miglioretti DL, Su YR, et al. Breast cancer screening using mammography, digital breast tomosynthesis, and magnetic resonance imaging by breast density. JAMA Intern Med, 2024, 184(10): 1222-1231.
97. Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol, 2015, 25(12): 3669-3678.
98. Mariscotti G, Houssami N, Durando M, et al. Accuracy of mammography, digital breast tomosynthesis, ultrasound and MR imaging in preoperative assessment of breast cancer. Anticancer Res, 2014, 34(3): 1219-1225.
99. Alabousi M, Wadera A, Kashif Al-Ghita M, et al. Performance of digital breast tomosynthesis, synthetic mammography, and digital mammography in breast cancer screening: a systematic review and meta-analysis. J Natl Cancer Inst, 2021, 113(6): 680-690.
100. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA, 2014, 311(24): 2499-2507.
101. Kulkarni S, Freitas V, Muradali D. Digital breast tomosynthesis: potential benefits in routine clinical practice. Can Assoc Radiol J, 2022, 73(1): 107-120.
102. 張振華, 李曼, 劉文霞. 廣角DBT與MRI在致密型乳腺惡性腫瘤的影像學特征及診斷. 醫學影像學雜志 2023, 33(9): 1603-1607.
103. Expert Panel on Breast Imaging; Klein KA, Kocher M, et al. ACR Appropriateness Criteria? palpable breast masses: 2022 update. J Am Coll Radiol, 2023, 20(5S): S146-S163. doi: 10.1016/j.jacr.2023.02.013.
104. Aristokli N, Polycarpou I, Themistocleous SC, et al. Comparison of the diagnostic performance of Magnetic Resonance Imaging (MRI), ultrasound and mammography for detection of breast cancer based on tumor type, breast density and patient’s history: A review. Radiography (Lond), 2022, 28(3): 848-856.
105. 阮程曉, 鄭穎娟. 彩色多普勒超聲聯合全數字化乳腺X線攝影診斷乳腺癌的臨床價值分析. 腫瘤基礎與臨床, 2025, 38(2): 220-223.
106. 國家癌癥中心/國家腫瘤臨床醫學研究中心/中國醫學科學院北京協和醫學院腫瘤醫院, 《健康體檢與管理》雜志編委會, 中華醫學會健康管理學分會, 等. 乳腺癌機會性篩查規范路徑專家共識. 健康體檢與管理, 2024, 5(1): 1-13.
107. Brown AL, Vijapura C, Patel M, et al. Breast cancer in dense breasts: detection challenges and supplemental screening opportunities. Radiographics, 2023, 43(10): e230024. doi: 10.1148/rg.230024.
108. Lynge E, Vejborg I, Lillholm M, et al. Breast density and risk of breast cancer. Int J Cancer, 2023, 152(6): 1150-1158.
109. Hu Y, Yang Y, Gu R, et al. Does patient age affect the PPV3 of ACR BI-RADS ultrasound categories 4 and 5 in the diagnostic setting?. Eur Radiol, 2018, 28(6): 2492-2498.
110. Checka CM, Chun JE, Schnabel FR, et al. The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol, 2012, 198(3): W292-W295. doi: 10.2214/AJR.10.6049.
111. Schonberg MA, Marcantonio ER, Li D, et al. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol, 2010, 28(12): 2038-2045.
112. Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol, 2021, 22(7): e327-e340. doi: 10.1016/s1470-2045(20)30741-5.

Next Article
Quality control index for multidisciplinary precision diagnosis and treatment of breast cancer in Sichuan province (2025 edition)

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expert consensus on breast cancer screening in Chinese female with dense breast (2025 edition)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content